CTT-1057 Uses, Dosage, Side Effects and more
CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
| Trade Name | CTT-1057 |
| Generic | CTT-1057 |
| Type | |
| Formula | C28H40FN4O14P |
| Weight | Average: 706.6078 Monoisotopic: 706.226266725 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
